Latest Haemophilia Stories
An Educational Program Based on the Findings From the Hemophilia Experiences, Results, and Opportunities (HERO) Study Launched at NHF's 66th Annual Meeting NEW YORK and PLAINSBORO,
- Three-year findings regarding prophylaxis versus on-demand treatment in adults with hemophilia A WHIPPANY, N.J., Sept.
Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
National Hemophilia Foundation Encourages Patient Community to Take an Active Part in Strategies, Policies, and Programs Directly Affecting Their Lives at 66th Annual Meeting in Washington, DC
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions - MISSISSAUGA, ON, Aug.
PLAINSBORO, N.J., Aug.
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug.
First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/
The National Hemophilia Foundation (NHF) with the guidance of its Medical and Scientific Advisory Council (MASAC), today announced that it is initiating a multi-year project to develop evidence-based
LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.